Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | July 2009 |
| End Date: | August 2014 |
A Phase I, Multicenter, Open-Label, Dose-Escalation, Multidose Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non Hodgkin's Lymphoma
The purpose of this study is to determine if MDX-1203 is safe for the treatment of renal
cell carcinoma or non-hodgkin's lymphoma.
Multicenter, open-label, dose-escalation, multidose study of MDX-1203, a fully human
monoclonal antibody drug conjugate targeting the CD70 transmembrane cell-surface protein
which is highly expressed in ccRCC and B-NHL. MDX-1203 is composed of a human anti-CD70
monoclonal antibody covalently linked to a prodrug form of a cytotoxic deoxyribonucleic acid
(DNA) minor-groove binding agent (MGBA).
The study will consist of 3 periods: Screening (up to 28 days), Treatment (up to 17 cycles
or 2 years), and Follow-up (up to 6 months).
We found this trial at
5
sites
University of Maryland, Baltimore Welcome to the University of Maryland, Baltimore (UMB) founded in 1807...
Click here to add this to my saved trials
1500 E Medical Center Dr
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(734) 936-4000
University of Michigan Health Systems The University of Michigan is home to one of the...
Click here to add this to my saved trials
University of Chicago One of the world's premier academic and research institutions, the University of...
Click here to add this to my saved trials
Click here to add this to my saved trials
Yale University School of Medicine Founded in 1810, the Yale School of Medicine is a...
Click here to add this to my saved trials